With its liquid biopsy test FDA approved and monitoring and screening offerings poised for launch, the firm is turning its attention to tumor tissue testing.
Later this year, the inherited cardiovascular disease clinic also plans to implement a preventive genomics program with polygenic risk score and PGx testing.
Investigators reported that the classifier could correctly predict cancer type with over 94 percent accuracy and highlighted impacts in a commercially tested cohort.
The company had been working to expand its retrospective data over the last year and half and is now readying to move forward with prospective studies.
Backed by large public companies and growing prospective data, the first molecular blood tests to screen for multiple cancers are approaching commercialization.
The company hopes the data will help convince clinicians to adopt the algorithm in CRC as it pushes forward validations for other areas like pancreatic and ovarian tumors.
The company believes its tests can already help oncologists better assess post-surgery risk, though prospective validation would be necessary for broad claims.
